Clinical Research Directory
Browse clinical research sites, groups, and studies.
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
Sponsor: HELP Therapeutics Co., Ltd.
Summary
The purpose of this clinical study is to evaluate the feasibility, safety and efficacy of intramyocardial injection of human induce pluripotent stem cell-derived cardiomyocytes (HiCM-188) during coronary artery bypass grafting (CABG) surgery in patients with severe chronic ischemic heart failure.
Official title: Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes to Treat Severe Chronic Ischemic Heart Failure
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2023-09-05
Completion Date
2027-05-10
Last Updated
2026-02-10
Healthy Volunteers
No
Conditions
Interventions
HiCM-188 therapy
Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes (HiCM-188) during coronary artery bypass grafting surgery
Locations (1)
TEDA International Cardiovascular Hospital
Tianjin, Tianjin Municipality, China